Spain leads Europe in clinical trial authorizations in 2025, with significant growth in oncology and advanced therapies underpinned by regulatory innovations and a strong research network.
Spain leads Europe in clinical trial authorizations in 2025, with significant growth in oncology and advanced therapies underpinned by regulatory innovations and a strong research network.
Spain is finalizing major reforms in pharmaceutical legislation to enhance medicine affordability, supply security, and innovation access.
Spain leads Europe in multinational clinical trial authorizations in 2024, with 770 approvals and a key role in the upcoming FAST-EU initiative.
Grupo Fuertes-ELPOZO invests over €45 million in new biopharmaceutical facilities to extract essential medicines from pig by-products, advancing circular economy practices.
Spain's renowned health benefits stem from a holistic lifestyle and new cardiovascular medication research showing heart protection independent of weight loss.
Trump's U.S. pharmaceutical policies increase pressure on Spain and Europe, risking loss of competitiveness and prompting calls for urgent strategic action.
Spain's Pharmaceutical Industry Strategy celebrates its first anniversary with major steps forward in biopharma innovation, improved patient access, updated policies, and strengthened public-private collaboration.
At the La Toja Forum, leaders discussed Spain's competitiveness challenges and the critical need for innovation and political rationality to strengthen the economy and pharmaceutical sector.
Antimicrobial resistance is framed as an economic and investment risk, highlighting urgent need for action.
Farmaindustria's new plan seeks to attract pharmaceutical investment to Spain through strategic incentives and collaboration.
Spain faces urgent challenges in maintaining its biopharmaceutical R&D hub status amid growing competition.